This site is intended for healthcare professionals

CHMP negative for approval of Raylumis as a proposed treatment for pain associated with osteoarthritis.

Read time: 1 mins
Last updated:20th Dec 2021
Published:22nd Sep 2021
The European Medicines Agency has recommended the refusal of the marketing authorisation for Raylumis, a medicine intended for the treatment of pain associated with osteoarthritis.

Although Raylumis showed better pain relief and improved physical functioning in patients with osteoarthritis affecting the hip or knee compared with placebo, the difference was small. In addition, there was no improvement in pain relief and physical functioning when compared with NSAIDs. In terms of safety, patients on Raylumis were at an increased risk of side effects, such as rapid progressive osteoarthritis and joint replacement, compared with patients receiving placebo or NSAIDs

Therefore, the Agency’s opinion was that the benefits of Raylumis in patients with an insufficient response to NSAIDs or opioids were unclear and did not outweigh its risks and recommended refusing marketing authorisation.

Condition: Pain:Osteoarthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights